



OUTSOURCING

Emerging Clinical Trial Locations – China

Market dynamics and the changing healthcare and regulatory environment

By Paul Taylor Ph.D. MBA

Paul Taylor

Paul Taylor is an independent market analyst for the medical industry with a BSc and PhD in Biochemistry from the University of Liverpool and an MBA from Oxford Brookes University. Dr Taylor has worked in the medical industry as a senior marketing executive for 20 years creating and implementing strategic business and marketing plans for major multinational medical device companies before establishing himself as an independent research analyst.

For the last ten years Dr Taylor has focused on the structure, organization and functioning of the European healthcare systems with particular focus on reimbursement systems, analyzing specific European product market segments and advising/preparing strategic business and marketing plans for international pharmaceutical, medical devices and healthcare technology companies.

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Emerging clinical trial locations - China

Executive summary	10	
Introduction	10	
Conducting clinical trials in emerging markets	11	
China	12	
Chapter 1	Introduction	14
Summary		14
Introduction		15
Generic competition		15
Intellectual property protection		15
Managing regulatory compliance		17
Cost containment and government funding restrictions		18
Obtaining and maintaining competitive advantage		18
Recruitment and retention of a skilled workforce		19
Improvement to R&D productivity		20
High risks and costs associated with drug development		20
Escalating costs of clinical trials		20
Global increase in the number of clinical trials conducted		23
Longer R&D timelines		24
Increased attrition rates during R&D		26
Clinical trial study design and planning		27
Clinical trial study design		27
Clinical trial study protocol		28
Clinical trial sponsors		28
Identifying and recruiting patients		28
Role of CROs		29
Information technology and new technology platforms		29
Drivers of development		30
Advantages associated with EDC		30
Advantages of electronic Clinical Trial Management Systems (CTMS)		30
Cost saving		31
Issues and challenges		31

Electronic records and signatures	31
Integration and linkage of electronic systems	32
Security and confidentiality of patient data	32

Chapter 2 Conducting clinical trials in emerging markets 36

Summary	36
Introduction	37
Market drivers	39
Rapid recruitment of patients and clinical trial investigators	39
Significant cost benefits	41
Improving transparency and efficiency of regulatory systems	42
Harmonization and standardization of regulatory requirements	43
Expansion of CROs	44
Conducive hospital infrastructure and healthcare systems	46
Enhanced clinical site effectiveness	47
Future commercial value	49
Key barriers	50
Concerns over the clinical trial transparency	50
Publication bias	51
Selective reporting	52
Duplicate publication	53
Conflict of interest	53
Availability of demographic and epidemiology data	53
Critical components concerning capacity building	53
Assimilation of individual national regulations and guidelines	56
United States	56
Japan	57
European Union	58
Language translation	59
Ethical challenges	60
Health needs of the population under study	60
Respect for potential and enrolled subjects	61
Ethical oversight	61
Lack of review by institutional review board (IRB)	61
Absence of informed consent	62
Scientific validity	63
Inadequate protection of intellectual property	64
Clinical trial logistics	64
Import licenses and applications	64
Customs regulations	65
Storage, handling and distribution	66
Selecting an appropriate CRO	67
Patient enrolment	70
Site selection	70
Site activation	71

Patient recruitment	71
---------------------	----

Chapter 3 China 74

Summary	74
Introduction	75
Geographic	75
Political	75
Economic	76
Market dynamics	78
Vital statistics	78
Population statistics	78
Epidemiology and prevalence of major disease	78
Pharmaceutical market	80
CRO market	82
Overseas CROs	84
Joint venture companies	85
Local CROs	86
Clinical trial market	88
Market drivers	89
Rapid patient recruitment from large pool of treatment naïve patients	89
Well-trained and motivated clinical trial investigators	89
Major cost savings	89
Increasing importance of the pharmaceutical market in China	90
US government opens FDA offices in China	91
Financial support and incentives from the Chinese government	92
Creation of the Chinese Clinical Trial Register (CHiCTR)	92
Key barriers	94
Cultural and linguistic	94
Delays to application and gaining approval	94
Due diligence required to ensure intellectual property protection	95
Issues over importation and importation licenses	95
Monitor compliance of SFDA GCP with ICH GCP	95
Healthcare	96
Healthcare system	96
Overview	96
Healthcare reforms	98
Healthcare institutions	99
Hospital resources	100
Regulation	102
Regulatory authorities	102
State Food and Drug Administration (SFDA)	102
Department of drug registration	103
Clinical trial regulation	104
Application and approval of the new drug clinical trial study	104

	Registration approval for the manufacture of the new drug for market	105
Legislation		108
	Patent Law and WTO TRIPS	108
	Drug Administration Law of the People's Republic of China	111
Outlook		115

Chapter 4 Appendix 118

Introduction to clinical trials	118
Clinical trial phases	118
Phase I	118
Phase II	118
Phase III	119
Phase IV	119
What is a clinical trial	119
Clinical trials of pharmaceutical agents	120
Types of clinical trial	121
Pilot studies	121
Proof of concept (PoC) trials	121
Randomized clinical studies	121
Controlled clinical trials	121
Parallel studies	122
Parallel group trials	122
Cohort studies	122
Case control studies	122
Role of the chief investigator	123
Clinical trial protocol and procedure	123
Determination of the clinical trial size	124
Role of the coordinating centre and trials unit	124
Role of the trial coordinator	124
The trial principle investigator	125
Forms and data management	125
Trial data analysis and evaluation	126
Ethical issues and conduct of clinical trial research	126
Interpretation and publication of clinical trial results	127
Principle regulatory agencies	127
The European Agency for the Evaluation of Medicinal Products (EMEA)	127
The United States Food and Drug Administration (US FDA)	127
Japanese Ministry of Health, Labor and Welfare (MHLW)	128
Methodology statement	129
Primary Data and Information Gathering	129
Secondary data and information gathering	130
Definitions of Product-Life Cycle stages	132
Glossary of abbreviations and acronyms	133

List of Figures

Figure 1.1:	Key issues facing Pharma and Biotech companies	16
Figure 1.2:	Cost of bringing a drug to market (\$m), 1975-2008	21
Figure 1.3:	Pharmaceutical R&D expenditure (\$bn), 2004-2009e	22
Figure 1.4:	Biotechnology R&D expenditure (\$bn), 2004-2009e	22
Figure 1.5:	Cost of clinical trials in the US (\$bn), 2005-2011e	23
Figure 2.6:	Comparison of locations across selected countries	38
Figure 2.7:	Korean Food and Drug Administration (KFDA) Approval Process	43
Figure 2.8:	CRO Segment Leaders	45
Figure 2.9:	Enhanced clinical site effectiveness (patients per site) in the emerging countries	48
Figure 2.10:	Fewer ineffective sites in the emerging countries	48
Figure 2.11:	Critical components for capacity building/conducting clinical trials	54
Figure 2.12:	Assessing clinical trial location feasibility	55
Figure 2.13:	CRO selection criteria	70
Figure 3.14:	Administrative divisions of the People's Republic of China	77
Figure 3.15:	Pharma market in China (\$), 2007-2008	81
Figure 3.16:	CRO market in China (US\$), 2007-2012	83
Figure 3.17:	Cost of clinical trials (%) in China vs western countries	90
Figure 3.18:	The Chinese Healthcare System	97
Figure 3.19:	NRCMCS medical cover cost and benefits in China	99
Figure 3.20:	Current drug approval and evaluation process in China	105
Figure 3.21:	Application and approval procedure for clinical trials China	107
Figure 3.22:	Location of accredited sites for clinical trials in China	113

List of Tables

Table 2.1:	Demographics of selected emerging markets, 2007	40
Table 2.2:	Ethical principles & their application for research	62
Table 3.3:	China Population Projections (m people), 1950-2050	79
Table 3.4:	Ten leading causes of death in China, 2002	79
Table 3.5:	Prevalence of major cancers in China, 2007	80
Table 3.6:	Top 10 pharmaceutical companies (\$m) in China, 2008	82
Table 3.7:	Major multinational CROs operating in China	84
Table 3.8:	Local Chinese owned CROs	87
Table 3.9:	Number of healthcare institutions according to ownership China	100
Table 3.10:	Total number of hospitals by ranking China	101
Table 3.11:	Chinese government agencies responsible for drug regulation	102

